Lycia Therapeutics (NASDAQ:LYCA) Stock: Insider Venrock Healthcare Capital Par Acquires 8,305 Shares

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par bought 8,305 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were acquired at an average cost of $26.95 per share, for a total transaction of $223,819.75. Following the purchase, the insider directly owned 6,858,542 shares in the company, valued at $184,837,706.90. This trade represents a 0.12% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par purchased 9,004 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $26.28 per share, for a total transaction of $236,625.12.
• On Thursday, October 29th, Venrock Healthcare Capital Par purchased 1,000 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $26.33 per share, for a total transaction of $26,330.00.
• On Wednesday, October 28th, Venrock Healthcare Capital Par purchased 15,000 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $25.45 per share, with a total value of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par acquired 39,796 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $26.62 per share, with a total value of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par acquired 1,952,705 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $18.04 per share, with a total value of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par acquired 52,939 shares of Lycia Therapeutics stock. The shares were bought at an average price of $25.91 per share, for a total transaction of $1,371,649.49.

Lycia Therapeutics Stock Performance

Lycia Therapeutics stock opened at $28.80 on Friday. Lycia Therapeutics, Inc. has a 1 year low of $22.19 and a 1 year high of $36.49.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st.

About Lycia Therapeutics

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.